
January 6, 2025
Six-month priority review granted for CUTX-101 copper histidinate with PDUFA target action date set for June 30, 2025 CUTX-101 has potential to be the first FDA-approved treatment for Menkes disease, a rare and fatal pediatric disease Solana Beach, CA, Ahmedabad, India, and Miami, FL – January 6, 2025 — Sentynl Therapeutics, Inc. (“Sentynl”), a […]